DOI: 10.12890/2021_002424

Efficacy of Cannabinoids on Spasticity and Chronic Pain in a Patient with Co-occurrence of Multiple Sclerosis and Neurofibromatosis Type 1

Authors

  • Eleonora Virgilio Neurology Unit, Maggiore della Carità Hospital, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy
  • Domizia Vecchio Neurology Unit, Maggiore della Carità Hospital, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy
  • Paola Naldi Neurology Unit, Maggiore della Carità Hospital, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy
  • Roberto Cantello Neurology Unit, Maggiore della Carità Hospital, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy

virgilioeleonora88@gmail.com

Keywords

Multiple sclerosis, neurofibromatosis type 1, spasticity, chronic pain, cannabinoids

Abstract

Neurofibromatosis type 1 (NF1) is a rare autosomal dominant disease involving the skin and central nervous system (CNS), and also characterized by skeletal and spinal schwannomas that may cause chronic neurogenic pain. Furthermore, pain in NF1 is underestimated, even though it has an impact on quality of life. Multiple sclerosis (MS) is the most common acquired demyelinating disease that may in later stages present with refractory spasticity, particularly in the lower limbs. Oromucosal cannabinoid sprays are currently available for spasticity treatment in MS, with encouraging results on MS pain, but few data have been reported regarding the use of cannabinoids in NF1. We report the successful treatment of chronic neurogenic pain and spasticity in a patient with co-occurrence of NF1 and MS after a poor response to standard approaches.

View the entire article

Downloads

References

  1. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69(2):292–302. doi: 10.1002/ana.22366. PMID: 21387374; PMCID: PMC3084507.
  2. Buono FD, Grau LE, Sprong ME, Morford KL, Johnson KJ, Gutmann DH. Pain symptomology, functional impact, and treatment of people with neurofibromatosis type 1. J Pain Res 2019;12:2555–2561. doi: 10.2147/JPR.S209540. PMID: 31692483. PMCID: PMC6710538.
  3. Shofty B, Barzilai O, Khashan M, Lidar Z, Constantini S. Spinal manifestations of neurofibromatosis type 1. Childs Nerv Syst 2020;36(10):2401–2408. doi: 10.1007/s00381-020-04754-9. PMID: 32564155.
  4. Aboud T, Schuster NM. Pain management in multiple sclerosis: a review of available treatment options. Curr Treat Options Neurol2019;21(12):62. doi: 10.1007/s11940-019-0601-2. PMID: 31773455.
  5. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003;17(1):21–29. doi: 10.1191/0269215503cr581oa. PMID: 12617376.

Published

2021-05-13

Issue

Vol. 8 No. 5 (2021)

How to Cite

1.
Virgilio E, Vecchio D, Naldi P, Cantello R. Efficacy of Cannabinoids on Spasticity and Chronic Pain in a Patient with Co-occurrence of Multiple Sclerosis and Neurofibromatosis Type 1. EJCRIM [Internet]. 2021 May 13 [cited 2026 Nov. 3];8(5). Available from: https://ejcrim.com/index.php/ejcrim/article/view/2424